BACKGROUND The COVID-19 vaccines were rapidly developed and tested, but concerns about vaccine-related adverse events remain, especially in vulnerable groups like pregnant women, children, and those with certain health conditions. This review aims to summarize rates of such adverse events in individuals often not included in randomized clinical trials (RCT). METHOD From December 2019 to February 2022, we searched Embase and Medline for observational studies and RCTs on adverse events post-COVID-19 vaccination in vulnerable groups. We examined serious and non-serious events in individuals with specific medical conditions, infants, children, pregnant individuals, and socioeconomically disadvantaged individuals. Cumulative risks for all events were calculated. The Incidence rate (IR) and 95% confidence intervals were reported for those studies that met the follow-up period criteria based on the referenced literature. For events with data on exposed and unexposed groups, we calculated the odds ratio. Pooled incidence rates were calculated per 1000 person-days using a random-effects model. Sub-group analyses were conducted based on vaccine types and doses, with heterogeneity assessed using I2. FINDINGS Of the 4,254 papers, 235 met eligibility criteria, including 120 studies with 171,073 participants (113 observational, eight RCTs. We examined 17 severe and 7 non-severe adverse event categories. Lymphadenopathy (IR: 1.95[1.20;3.19]), autoimmune disease and multiple sclerosis flare-up (1.13 [0.47;2.68]), and cardiac symptoms (0.26[0.00;10.58]) were the most severe events. Allergic reactions were more common among autoimmune (7.03[4.10;12.06]) and cancer (4.87[2.21;10.76]) groups. vaccinees who received the second dose of vaccine had higher proportions of disease flare-ups (39.27 [18.08;85.31] vs 22.13 [10.22; 47.93]); cardiac symptoms (6.11[2.05-18.22] vs 3.78[2.53-5.65]); and cardiac events (5.34[1.69;16.90] vs 5.05[1.40,18.19]) in observational studies. INTERPRETATION This review highlights COVID-19 vaccine safety in vulnerable populations, enhancing vaccination strategies. Further real-world research is needed to validate and extend our findings, especially in addressing safety gaps among vulnerable groups.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

our study is a systematic review searching MEDLINE and Embase databases

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript